Word

AUTOLUS

Status

Registered

Status Code

700

Status Date

Tuesday, July 9, 2024

Serial Number

79380366

Registration Number

7435787

Registration Date

Tuesday, July 9, 2024

Mark Type

4

Filing Date

Tuesday, September 5, 2023

Published for Opposition

Tuesday, April 23, 2024

Trademark Owner History

Autolus Limited - Original Registrant

Classifications

40 Custom manufacture of therapeutic drugs, namely, cell therapies, cancer therapies and cancer vaccines

5 Medical and veterinary preparations for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for cell therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for cancer therapies for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; cells for medical or clinical use, namely, cells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; antibodies for medical purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors, namely, culture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; vaccines

44 Medical services; veterinary services; medical and veterinary services in the nature of extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes, namely, medical services relating to the removal, treatment and processing of human and animal cells; medical and veterinary services in the nature of reinsertion of cells into human and animal patients; providing medical advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines

42 Scientific and technological services and research and design relating thereto, namely, medical research, scientific research, analysis and testing in the field of human and animal cell, gene and cancer therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell, gene and cancer therapies; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, including personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services

Trademark Events

Oct 5, 2023

Sn Assigned For Sect 66a Appl From Ib

Oct 10, 2023

New Application Office Supplied Data Entered

Oct 14, 2023

Application Filing Receipt Mailed

Jan 25, 2024

Assigned To Examiner

Jan 25, 2024

Non-Final Action Written

Jan 26, 2024

Non-Final Action (Ib Refusal) Prepared For Review

Feb 14, 2024

Refusal Processed By Mpu

Feb 14, 2024

Non-Final Action Mailed - Refusal Sent To Ib

Feb 29, 2024

Teas Response To Office Action Received

Feb 29, 2024

Correspondence Received In Law Office

Mar 1, 2024

Teas/Email Correspondence Entered

Mar 5, 2024

Refusal Processed By Ib

Mar 16, 2024

Approved For Pub - Principal Register

Apr 3, 2024

Notification Of Notice Of Publication E-Mailed

Apr 23, 2024

Published For Opposition

Apr 23, 2024

Official Gazette Publication Confirmation E-Mailed

Jul 9, 2024

Registered-Principal Register

Jul 9, 2024

Notice Of Registration Confirmation Emailed